title: Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.
abstract: BACKGROUND
  New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is not well understood.
  
  
  OBJECTIVE
  To identify the relative importance of frequency of administration, efficacy, and other treatment characteristics among candidates for prophylactic treatment for hemophilia A and B.
  
  
  METHODS
  An Internet survey was conducted among hemophilia patients and the parents of pediatric hemophilia patients in Australia, Canada, and the US. A monadic conjoint task was included in the survey, which varied frequency of administration (three, two, or one time per week for hemophilia A; twice weekly, weekly, or biweekly for hemophilia B), efficacy (no bleeding or breakthrough bleeding once every 4 months, 6 months, or 12 months), diluent volume (3 mL vs 2.5 mL for hemophilia A; 5 mL vs 3 mL for hemophilia B), vials per infusion (2 vs 1), reconstitution device (assembly required vs not), and manufacturer (established in hemophilia vs not). Respondents were asked their likelihood to switch from their current regimen to the presented treatment. Respondents were told to assume that other aspects of treatment, such as risk of inhibitor development, cost, and method of distribution, would remain the same.
  
  
  RESULTS
  A total of 89 patients and/or parents of children with hemophilia A participated; another 32 were included in the exercise for hemophilia B. Relative importance was 47%, 24%, and 18% for frequency of administration, efficacy, and manufacturer, respectively, in hemophilia A; analogous values were 48%, 26%, and 21% in hemophilia B. The remaining attributes had little impact on preferences.
  
  
  CONCLUSIONS
  Patients who are candidates for prophylaxis and their caregivers indicate a preference for reduced frequency of administration and high efficacy, but preferences were more sensitive to administration frequency than small changes in annual bleeding rate.
authors.affiliation: Advanced Methods, Kantar Health, Epsom, Surrey, UK.
authors.forename: Roberto
authors.initials: R
authors.lastname: Furlan
authors.affiliation: Global Health Economics and Outcomes Research, Biogen, MA, USA.
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Krishnan
authors.affiliation: Health Outcomes, Kantar Health, Milan, Italy.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Vietri
keywords: breakthrough bleeds; conjoint analysis; frequency of administration; prophylaxis; treatment preferences